Health Topics — Gut Health
IBD, IBS, and What the Cannabinoid Research Has Examined
For the person with inflammatory bowel disease or IBS who wants honest information — where the evidence is genuinely strong, where it isn't, and what the distinction between these two conditions means for the research.
IBD and IBS are often conflated — by patients searching for answers, by content that addresses both without distinguishing them, and occasionally by clinicians who move too quickly past the difference. They are not the same condition, they are not managed the same way, and the cannabinoid research relevant to each is different. Knowing which one you have changes which research is most directly relevant to you.
Inflammatory bowel disease — Crohn's disease and ulcerative colitis — involves documented, measurable inflammation and tissue damage in the gastrointestinal tract. It is diagnosed through imaging, endoscopy, and biopsy. The inflammation is real, visible, and the primary driver of symptoms. IBD is an immune-mediated condition with a complex genetic and environmental basis, managed with anti-inflammatory medications, immunosuppressants, and biological agents. It has periods of remission and flare, and managing the inflammatory process is central to treatment.
Irritable bowel syndrome — IBS — is a functional gastrointestinal disorder. The symptoms are real and often significant: cramping, bloating, altered bowel habits, pain. But there is no structural damage, no measurable inflammation, no abnormality visible on colonoscopy. IBS is a disorder of gut function — of motility, of pain sensitivity, of gut-brain axis communication — not of gut tissue integrity. This distinction matters enormously for understanding what research applies.
The CBG research in IBD — what it found and what it means
CBG has more specific, more compelling gut research than any other cannabinoid in this archive — and it is in IBD, not IBS. The Borrelli study (2013) examined CBG in a mouse model of colitis using a well-established chemical irritant to produce gut inflammation. CBG-treated animals showed measurably reduced inflammatory markers, reduced gut permeability — the breakdown of the intestinal wall barrier that allows bacterial products to enter the bloodstream — reduced weight loss, and less tissue damage in the colon compared to untreated animals.
The mechanism involved CB2 receptor activation in gut immune cells and PPAR-γ activation — the same anti-inflammatory pathways documented in CBG's broader inflammatory research. The gut's immune compartment is CB2-rich, and CB2 activation in inflamed gut tissue modulates the cytokine signals that drive the inflammatory cycle in IBD. This is not speculative — it is documented in the model, and the mechanism is consistent with everything else known about CBG's anti-inflammatory profile.
This is also an animal model finding. The distance from a colitis mouse model to human Crohn's disease or ulcerative colitis is real and significant. Mouse models of IBD are useful for establishing mechanisms and identifying candidate compounds. They are not a substitute for human trials. No controlled human trial of CBG in IBD has been conducted as of 2026.
IBS — a different research picture
Because IBS is a functional disorder — involving gut motility, pain sensitivity, and gut-brain communication rather than tissue inflammation — the relevant research thread is different. CBD's mechanisms are more directly applicable here: its interaction with CB1 receptors in the enteric nervous system, which govern gut motility and pain thresholds, and its 5-HT1A serotonin activity, which is relevant to the gut-serotonin system that IBS disrupts.
Small human studies and observational data suggest that cannabis use is associated with improved IBS symptoms in some patients. These are not controlled trials and cannot establish causation. They establish that a pattern exists and that the mechanism is plausible. What controlled trial evidence would look like for CBD or CBG in IBS is an open research question.
On IBD management and clinical care
IBD is a serious, diagnosed condition managed by gastroenterologists with medications that have established clinical trial evidence. Nothing in this archive is relevant to IBD management decisions without discussion with your treating clinician. Cannabis and cannabinoid use can interact with IBD medications, and your gastroenterologist needs to know if you are using them.
IBS similarly benefits from clinical assessment. Other conditions can present with IBS-like symptoms, and accurate diagnosis matters before management decisions are made.
For a clinician or practitioner reading this: the IBD research on CBG is mechanistically coherent and the Borrelli animal model findings are published and peer-reviewed. The CB2 receptor upregulation in inflamed gut tissue — the body apparently reaching for more endocannabinoid regulation in the presence of gut inflammation — is a consistent research finding across IBD models. The human trial gap is real and significant.
IBD and IBS are different conditions with different research pictures. CBG's most specific gut evidence is in IBD — animal model, mechanistically grounded, no human trial. CBD's most relevant gut mechanisms are in IBS — functional motility and serotonin signaling, small and inconclusive human data. Knowing which applies to you is the first step to reading the research honestly. The mechanism article goes into the IBD evidence in full biochemical detail for those who want it.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.